A new genetic study is bringing the brain’s movement-control circuitry into sharper focus, suggesting that a person’s risk of developing sudden movement disorders after taking antipsychotic medication may be partly written into their DNA. Researchers investigated genetic variants linked to the substantia nigra, a small but crucial structure deep within the midbrain, and identified polymorphisms associated with acute antipsychotic-induced movement disorders in people with schizophrenia. The findings, generated through a genome-wide association study and tested across multiple ancestral populations, could help explain why some patients develop severe motor reactions while others taking similar medicines do not.
Antipsychotic drugs remain among the most important treatments for schizophrenia and other psychotic disorders. Their therapeutic effect is closely tied to the dopamine system, particularly the blockade of dopamine D2 receptors in brain circuits involved in hallucinations, delusions and disorganized thinking. However, dopamine also regulates movement. When dopamine signaling is disrupted in motor pathways, patients may experience extrapyramidal symptoms, a group of drug-related movement problems that can include muscle stiffness, tremor, restlessness, spasms and involuntary contractions. Acute dystonia can appear within hours or days of treatment, while drug-induced parkinsonism and akathisia may emerge over a longer period. These reactions can be painful, frightening and serious enough to cause patients to stop treatment.
The substantia nigra is central to this biological puzzle. Neurons in its pars compacta region produce dopamine and project to the striatum, a part of the basal ganglia that helps initiate and fine-tune movement. The most familiar example of substantia nigra dysfunction is Parkinson’s disease, in which the progressive loss of dopaminergic neurons produces tremor, rigidity and slowed movement. Antipsychotic-induced motor disorders are not caused by the same neurodegenerative process, but they can expose vulnerabilities in the same dopamine-dependent circuitry. Genetic differences affecting dopamine production, transport, receptor activity, neuronal survival or synaptic signaling could therefore influence how strongly an individual reacts when antipsychotic medication changes dopamine transmission.
To investigate that possibility, the researchers used a genome-wide association study, or GWAS, a method that scans hundreds of thousands or millions of DNA markers across the genomes of affected and unaffected individuals. Instead of testing one candidate gene at a time, GWAS searches broadly for single-nucleotide polymorphisms, commonly called SNPs, that occur more often in people with a particular trait. In this case, the trait was the development of acute movement disorders after antipsychotic exposure. The investigators then focused their interpretation on genes and biological signals connected with the substantia nigra, creating a bridge between statistical associations and the neurobiology of movement.
The study’s central message is that genetic variation in substantia nigra-related pathways may contribute to treatment-emergent motor symptoms in schizophrenia. The associated variants do not function as simple diagnostic switches, and carrying one does not mean that a patient will inevitably develop dystonia, akathisia or parkinsonism. Instead, such variants are more likely to alter probability by influencing how neurons respond to dopamine blockade, how efficiently medicines are metabolized or how resilient motor circuits are under pharmacological stress. The research therefore points toward a polygenic model in which many genetic effects, each potentially modest on its own, combine with medication dose, treatment duration, age, sex, previous exposure and other clinical factors.
A particularly important feature of the work is its multi-ancestry validation. Genetic studies have historically been dominated by participants of European ancestry, a limitation that can make risk predictions less reliable for people from other populations. The same DNA marker may have different frequencies, neighboring genetic patterns or functional relationships across ancestries. By testing whether signals identified in one group could be observed in additional ancestral populations, the researchers addressed one of the most important challenges in modern psychiatric genetics: determining whether a finding reflects a broadly shared biological mechanism or a population-specific statistical artifact. Cross-ancestry replication strengthens confidence in the underlying association, although it does not eliminate the need for larger studies.
The results could eventually support a more individualized approach to antipsychotic prescribing. At present, clinicians estimate movement-disorder risk using factors such as the chosen drug, dosage, treatment history and the patient’s neurological profile. A validated genetic risk model might one day add another layer of information before therapy begins, helping clinicians identify patients who require closer monitoring or who may benefit from a medication with a lower propensity to cause motor symptoms. It could also encourage earlier intervention when restlessness, rigidity or involuntary contractions first appear. However, the study is not yet a ready-to-use clinical test. Genetic associations must be replicated, their biological mechanisms must be demonstrated, and prediction models must prove that they improve care rather than simply produce additional uncertainty.
The findings also highlight the complexity of translating GWAS discoveries into biology. A SNP associated with a clinical outcome is not necessarily the mutation responsible for that outcome. It may be located near a functional gene, alter gene regulation, influence how DNA is packaged or merely be inherited alongside the causal variant through linkage disequilibrium. Researchers therefore need follow-up experiments in neuronal cells, brain tissue, organoids and carefully designed animal models to determine whether the implicated genes change dopamine signaling in the substantia nigra. Integrating genomic data with transcriptomics, epigenetics and pharmacological information could reveal whether the variants affect gene expression, receptor sensitivity, mitochondrial function, synaptic plasticity or the ability of neurons to withstand dopamine disruption.
For patients and families, the work offers a potentially important shift in the way adverse drug reactions are understood. Acute movement disorders are sometimes interpreted as signs of poor adherence, anxiety or worsening psychiatric illness, even though they may be direct biological effects of treatment. A genetic contribution would reinforce the idea that these reactions are not a matter of willpower and should not be dismissed. The study does not undermine the value of antipsychotic medicines, which can be life-changing and lifesaving, but it underscores the need to balance psychiatric benefits against neurological side effects. As larger and more diverse datasets become available, the long-term goal will be to make antipsychotic treatment safer, more predictable and more precisely matched to each patient’s biology.
Subject of Research: Genetic factors associated with acute antipsychotic-induced movement disorders in people with schizophrenia, with a focus on substantia nigra-related genes and pathways.
Article Title: Substantia nigra related gene polymorphisms associated with antipsychotic-induced acute movement disorders: a genome-wide association study and multi-ancestry validation in schizophrenia
Article References: Research article identified by DOI 10.1186/s40779-025-00636-w.
Image Credits: AI Generated
DOI: 10.1186/s40779-025-00636-w
Keywords: Schizophrenia; antipsychotic-induced movement disorders; extrapyramidal symptoms; substantia nigra; dopamine; genome-wide association study; GWAS; genetic polymorphisms; pharmacogenomics; multi-ancestry validation.
